Approved for Rheumatoid arthritis (moderate to severe, in adults who had inadequate response to methotrexate), Psoriatic arthritis (active, in adults who had inadequate response to DMARDs), Ulcerative colitis (moderate to severe, in adults who had inadequate response to TNF blockers). Tofacitinib is a Janus kinase (JAK) inhibitor that preferentially inhibits JAK1 and JAK3, with lesser activity…
Loading full data from Know Your Drugs Institute…